Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAMe in Alcoholic Liver Disease
NCT00573313Phase 3Completed
- Sponsor
- University of California, Davis
- Start
- Sep 2005
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in alcoholic liver disease (ALD) comparing S-adenosylmethionine with Placebo (2 arms). Primary endpoint: Changes in Serum AST Levels at 24 weeks. Started Sep 2005; status: completed.
02
Drugs
S-adenosylmethionine
03
Conditions
alcoholic liver disease (ALD)
Beyond the preview
Go deeper on NCT00573313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00573313.